Screening for hereditary hemochromatosis: are DNA-based tests the answer?
Universal screening for hereditary hemochromatosis (HH) has been proposed by many experts, with understandable enthusiasm: HH can cause fatal complications, which are preventable with early treatment. The disorder involves excess iron accumulation that can result in tissue iron overload, with secondary cirrhosis, diabetes, heart failure, impotence and arthritis. These complications are preceded by years of iron accumulation, and most are believed to be preventable by removal of excess iron by phlebotomy. Thus, early identification and treatment - the quintessential functions of health screening - seem to make sense for HH. However, the available screening tests are imperfect. While they can identify many persons at increased risk from HH, the proportion that will develop serious clinical manifestations related to iron overload is not known with certainty. DNA-based tests do not provide a simple resolution to these questions.
Burke
W
W
Department of Medicine Box 354765, University of Washington, 4245 Roosevelt Way NE, Seattle, WA 98105, USA. wburke@u.washington.edu
Franks
A L
AL
Bradley
L A
LA
D005820:Genetic Testing; D006432:Hemochromatosis / Q000175:diagnosis* / Q000235:genetics*; D006801:Humans; D012307:Risk Factors; D014168:Transferrin / Q000378:metabolism
D014168:Transferrin